Abstract
Given the prevalence of osteolytic bone disease in multiple myeloma (MM), novel therapies targeting bone microenvironment are essential. Previous studies have identified activin A to be of critical importance in MM-induced osteolysis. Lenalidomide is a known and approved treatment strategy for relapsed MM. Our findings demonstrate that lenalidomide acts directly on bone marrow stromal cells via an Akt-mediated increase in Jun N-terminal kinase-dependent signaling resulting in activin A secretion, with consequent inhibition of osteoblastogenesis. Here, we attempted to augment the antitumor benefits of lenalidomide while overcoming its effects on osteoblastogenesis by combining it with a neutralizing antibody to activin A. Increased activin A secretion induced by lenalidomide was abrogated by the addition of activin A-neutralizing antibody, which effectively restored osteoblast function and inhibited MM-induced osteolysis without negating the cytotoxic effects of lenalidomide on malignant cells. This provides the rationale for an ongoing clinical trial (NCT01562405) combining lenalidomide with an anti-activin A strategy.
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 1715-1721 |
Seitenumfang | 7 |
Fachzeitschrift | Leukemia |
Jahrgang | 27 |
Ausgabenummer | 8 |
DOIs | |
Publikationsstatus | Veröffentlicht - Aug. 2013 |
Extern publiziert | Ja |
ASJC Scopus Sachgebiete
- Hämatologie
- Onkologie
- Krebsforschung